Company profile for Luye Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology, cardiovascular and other therapeutic areas. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities. R&D centers in China, the U.S. and Europe with a robust pipeline of 30+ drug candidates...
Luye Pharma Group, a member of Luye Life Sciences Group, is an international pharmaceutical company with a focus on targeting central nervous system (CNS), oncology, cardiovascular and other therapeutic areas. Global R&D, global manufacturing, and the global sale of innovative medications are the company’s three main strategic priorities. R&D centers in China, the U.S. and Europe with a robust pipeline of 30+ drug candidates in China and 10+ drug candidates overseas. A series of innovative antibody and biosimilar products are under development. Several new drugs and new formulations in CNS and Oncology therapeutic areas.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
22F, Gubei International Fortune Center II, Hongqiao Road 1438, Changning Dist...
Telephone
Telephone
(86)21-6237-6350
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/luye-pharma-announces-us-launch-of-erzofri-paliperidone-palmitate-extended-release-injectable-suspension-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder-302421464.html

PR NEWSWIRE
07 Apr 2025

https://www.prnewswire.com/news-releases/luye-pharma-announces-us-fda-approval-of-erzofri-paliperidone-palmitate-extended-release-injectable-suspension-for-treating-schizophrenia-and-schizoaffective-disorder-302208155.html

PR NEWSWIRE
28 Jul 2024

https://www.biospectrumasia.com/news/25/23688/chinas-luye-pharma-partners-with-korea-based-myung-in-pharm-to-improve-alzheimers-related-dementia-treatment.html

BIOSPECTRUM ASIA
07 Feb 2024

https://www.biospectrumasia.com/news/25/22232/luye-pharma-duopharma-to-expand-accessibility-of-cholesterol-management-products-in-malaysia.html

BIOSPECTRUM ASIA
05 Apr 2023

https://www.pharmaceutical-technology.com/news/fda-schizophrenia-treatment-rykindo/

PHARMACEUTICAL TECHNOLOGY
16 Jan 2023

https://www.biospectrumasia.com/news/25/21113/luye-pharma-enters-into-new-partnership-with-ici-pakistan-for-mental-healthcare.html

BIOSPECTRUMASIA
27 Sep 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty